APA (7th ed.) Citation

E, D. C., GW, C., E, H., M, S., T, G., M, V., . . . PW, H. (2025). Dupilumab versus omalizumab in patients with chronic rhinosinusitis with nasal polyps and coexisting asthma (EVEREST): A multicentre, randomised, double-blind, head-to-head phase 4 trial. The Lancet. Respiratory medicine, 13(12), 1067. https://doi.org/10.1016/S2213-2600(25)00287-5

Chicago Style (17th ed.) Citation

E, De Corso, et al. "Dupilumab Versus Omalizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma (EVEREST): A Multicentre, Randomised, Double-blind, Head-to-head Phase 4 Trial." The Lancet. Respiratory Medicine 13, no. 12 (2025): 1067. https://doi.org/10.1016/S2213-2600(25)00287-5.

MLA (9th ed.) Citation

E, De Corso, et al. "Dupilumab Versus Omalizumab in Patients with Chronic Rhinosinusitis with Nasal Polyps and Coexisting Asthma (EVEREST): A Multicentre, Randomised, Double-blind, Head-to-head Phase 4 Trial." The Lancet. Respiratory Medicine, vol. 13, no. 12, 2025, p. 1067, https://doi.org/10.1016/S2213-2600(25)00287-5.